IP Verse

Methods For Treating Atopic Dermatitis By Administering An Il-4R Antagonist - EP2892927

The patent EP2892927 was granted to Regeneron Pharmaceuticals on May 9, 2018. The application was originally filed on Sep 4, 2013 under application number EP13765844A. The patent is currently recorded with a legal status of "Revoked".

EP2892927

REGENERON PHARMACEUTICALS
Application Number
EP13765844A
Filing Date
Sep 4, 2013
Status
Revoked
Jan 3, 2020
Grant Date
May 9, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

BREUERFeb 6, 2019BREUERADMISSIBLE

Patent Citations (4) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
INTERNATIONAL-SEARCH-REPORTWO2010053751
OPPOSITIONWO0192340
OPPOSITIONWO2010053751
OPPOSITIONWO2014039461

Non-Patent Literature (NPL) Citations (26) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
INTERNATIONAL-SEARCH-REPORT- "Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis", 71ST ANNUAL MEETING OF THE AMERICAN ACADEMY OF DERMATOLOGY,, (20130302), pages 1 - 3, URL: http://files.shareholder.com/downloads/REGN/2689212012x0x640531/794a7e54-6904-416b-ba38-a4ccc1726852/REGN_News_2013_3_2_General_Releases.pdf, XP007922251 [XP] 1-80,86-92,123-152 * the whole document *
INTERNATIONAL-SEARCH-REPORT- TARUNDEEP KAKKAR ET AL, "Population PK and IgE Pharmacodynamic Analysis of a Fully Human Monoclonal Antibody Against IL4 Receptor", PHARMACEUTICAL RESEARCH, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NL, (20110521), vol. 28, no. 10, doi:10.1007/S11095-011-0481-Y, ISSN 1573-904X, pages 2530 - 2542, XP019950375 [A] 1-80,86-92,123-152 * the whole document *
INTERNATIONAL-SEARCH-REPORT- EUROPEAN DERMATO-EPIDEMIOLOGY NETWORK SCHMITT ET AL, "What are the best outcome measurements for atopic eczema? A systematic review", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, ELSEVIER, AMSTERDAM, NL, (20071201), vol. 120, no. 6, doi:10.1016/J.JACI.2007.08.011, ISSN 0091-6749, pages 1389 - 1398, XP022383435 [A] 1-80,86-92,123-152 * the whole document *
INTERNATIONAL-SEARCH-REPORT- TAKASHI KAKINUMA ET AL, "Thymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activation-regulated chemokine level is closely related with disease activity", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, (20010301), vol. 107, no. 3, doi:10.1067/mai.2001.113237, ISSN 0091-6749, pages 535 - 541, XP055091226 [A] 1-80,86-92,123-152 * abstract * * figure 1 *
INTERNATIONAL-SEARCH-REPORT- K. JAHNZ-ROZYK ET AL, "Serum thymus and activation-regulated chemokine, macrophage-derived chemokine and eotaxin as markers of severity of atopic dermatitis", ALLERGY, (20050501), vol. 60, no. 5, doi:10.1111/j.1398-9995.2005.00774.x, ISSN 0105-4538, pages 685 - 688, XP055091216 [A] 1-80,86-92,123-152 * abstract * * table 1 *
INTERNATIONAL-SEARCH-REPORT- J. CORREN ET AL, "A Randomized, Controlled, Phase 2 Study of AMG 317, an IL-4R Antagonist, in Patients with Asthma", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, (20100415), vol. 181, no. 8, doi:10.1164/rccm.200909-1448OC, ISSN 1073-449X, pages 788 - 796, XP055013586 [A] 1-80,86-92,123-152 * the whole document *
INTERNATIONAL-SEARCH-REPORT- ONG PECK Y, "Editorial update on emerging treatments of atopic dermatitis", EXPERT OPINION ON EMERGING DRUGS ENGLAND, INFORMA HEALTHCARE, UK, (20120601), vol. 17, no. 2, doi:10.1517/14728214.2012.668884, ISSN 1744-7623, pages 129 - 133, XP009171977 [X] 62,63,69,126,127,139 * page 129, paragraph l * * table 1 * [Y] 12-15,26-29,35-38,55-58,65-68,74-77,91,130-133,149-152 [I] 1-11,16-25,30-34,39-54,59-61,64,70-73,78-80,86-90,92,123-125,128,129,134-138,140-148
OPPOSITION- A Garriga, "71st ANNUAL MEETING OF THE AMERICAN ACADEMY OF DERMATOLOGY (AAD)", Drugs of the Future, vol. 38, no. 4, (20130000), pages 275 - 279, XP055566346
OPPOSITION- ANTONIU, "Pitrakinra, a dual IL -4/ IL -13 antagonist for the potential 2010 treatment of asthma and eczema", Current Opinion in Investiga- tional Drugs, (20100000), vol. 11, no. 11, pages 1286 - 1294, XP009160470
OPPOSITION- "A Phase 2a Study to Investigate the Effects of Repeated Administration of AeroDerm in Subjects With Atopic Eczema", ClinicalTrials.gov, (20080513), XP055566335
OPPOSITION- Beck et al., "Systemic treatment of adult patients with severe atopic dermatitis with the IL-4Ralpha mAb, dupilumab, results in rapid and sustained improvements in disease signs and symptoms, abstarct 1049", International Investigative Dermatology, (20130508), XP055566302
OPPOSITION- "British Society for Allergy and Clinical Immunology (BSACI) Ab- stracts of the 2013 Annual Meeting (dated 8 to 10 July 2013", Clin- ical & Experimental Allergy, vol. 43, (20131122), pages 1428 - 1472, URL: https://onlinelibrary.wiley.eom/toc/13652222/2013/43/12
OPPOSITION- Charles Bankhead, "IL-4 Antibody Tames Atopic Dermatitis", Medpage Today Article, (20130303), URL: https://www.medpagetodaY.com/meetingcoverage/aad/37636, XP055566311
OPPOSITION- Hamilton et al., "Biomarkers elevated in atopic dermatitis (AD) are reduced by therapeutic blockade of IL-4 receptor a (IL-4ra) signaling with dupilumab in patients with moderate-to-severe AD, abstract 1042", International Investigative Dermatology, Edinburgh, (20130508), XP055566280
OPPOSITION- Hamilton et al., "Blocking IL-4Ralpha with dupilumab (REGN668/SAR231893) rapidly suppresses major pathogenic pathways in severe atopic dermatitis, abstract 1048", International Investigative Dermatology, (20130508), XP055566293
OPPOSITION- "Human Clinical Research and Therapeutics", Journal of May 2013 Investigative Dermatology, (20130000), vol. 133, no. 1, pages S159 - S190
OPPOSITION- Journal of Allergy & Clinical Immunology; Abstracts at conference, (20130200), URL: https://www.jacionline.org/issue/S0091-6749(13)X0013-2
OPPOSITION- "NCT01548404 Study of REGN668 in Adult Patients With Intrinsic Moderate-toSevere Atopic Dermatitis", ClinicalTrials.gov, (20120307), XP055566321
OPPOSITION- "Sanofi and Regeneron Report Positive Proof- of-Concept Data for Dupilumab, an IL -4R alpha Antibody, in Atopic Dermatitis", Regeneron, (20130302), URL: https://newsroom.regeneron.com/news-releases/news-release-details/sanofi-and-regeneron-report-positive-proof-concept-data, XP055566341
OPPOSITION- "Study of Dupilumab in Adult patients With Extrinsic Moderate-toSevere Atopic Dermatitis", ClinicalTrials.gov, (20150827), XP05566332
OPPOSITION- "Study to Assess the Safety of REGN668 (SAR231893) Administered Concomitantly With Topical Corticostroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD) (NCT01639040)", ClinicalTrials.org, (20120711), XP055566394
OPPOSITION- Yosipovitch et al., "IL-4Ralpha mAb dupilumab (REGN668/SAR231893) for the Treatment of Severe Aropic Dermatitis Itch, abstract 1050", International Investigative Dermatology, (20130508), XP055566307
OPPOSITION- NGUYEN, "Future Forms of Immunotherapy and Immunomodulators in Allergic Disease", Immunol Allergy Clin N Am, (20110000), vol. 31, pages 343 - 365, XP055566273
OPPOSITION- JOOST, "Cyclosporine in atopical dermatitis", British Journal of Dermatology, (19920000), vol. 27, no. 6, pages 634 - 640, XP055566410
OPPOSITION- NGUYEN, "Immune modulation for treatment of allergic disease", Immunological Reviews, (20110000), vol. 242, pages 258 - 271, XP055143463
OPPOSITION- ONG, "Editorial update on emerging treatments of atopic dermatitis", Expert Opinion on Emerging Drugs, (20120000), vol. 17, no. 2, pages 129 - 133, XP009171977

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents